LRRK2 and Parkinson disease: (R1441C) LRRK2 or (G2019S) LRRK2 transgenic mouse at the age of 12-16 months displayed parkinsonism phenotypes of motor dysfunction and cell death of SNpc dopaminergic neurons [14,15].